Geneious Biologics to showcase new capability in Boston
Geneious Biologics to showcase major new capability in Boston
AUCKLAND, NZ – April 17, 2018 – Bioinformatics software company Biomatters today announced it will host an exhibit at the Protein Engineering Summit (PEGS) in Boston to showcase new functionality in its Geneious Biologics software for antibody screening and discovery.
Since its launch at the PEGS Boston conference last year, Geneious Biologics has not only extended the software’s Sanger-based analysis tools but also introduced major new capability around next generation sequencing (NGS).
Geneious Biologics is engineered to intelligently manage and process large-scale NGS data sets. This allows users to quickly and accurately understand the diversity and quality of their antibody libraries and immune repertoires – ultimately improving the speed and accuracy of therapeutic antibody discovery.
Geneious Biologics’ advanced NGS analytics tools can:
• Analyze millions of raw NGS antibody sequences in minutes
• Preview, annotate, score and compare NGS sequences with no manual intervention
• Cluster and index annotated NGS sequences by sorting, filtering and querying these large datasets
• Compare NGS data sets and plot results of germline, diversity and region frequency
• Discover high-level trends in large-scale antibody NGS data sets and drill down into individual sequences
• Associate assay data with sequences to gain insights into antibody candidate efficacy
The PEGS conference will be held at the Seaport Convention Center in Boston from Monday, 30 April to Thursday, 3 May 2018.
Geneious Biologics is a next generation cloud software solution purpose-built, in collaboration with industry partners, for commercial antibody discovery and screening. Delivered through a modern intuitive, user-friendly web interface, the platform provides a fully managed data platform and informatics system in a secure cloud computing infrastructure. The architecture of the software delivers scalable data management and computation, enabling organizations to increase their process efficiencies and accelerate their drug discovery. For more information about Geneious Biologics check out the NGS fact sheet or visit www.geneiousbiologics.com.
Biomatters (www.biomatters.com) empowers its customers with software that transforms biological data into knowledge and actionable insights. The company’s Geneious software suite is used by over 3,000 companies, universities, and institutes in more than 100 countries. Geneious Biologics integrates with Biomatters’ existing Geneious DNA analysis tools and leverages the company’s deep expertise in delivering solutions that meet customers’ real-life needs.